# Systematic identification of variant-specific RNA structure-small molecule interactions exemplified by RNA G-quadruplexes

**Authors:** Emi Miyashita, Kazumitsu Onizuka, Yutong Chen, Hiroki Yoshida, Hina Hatayama, Shunya Ishikawa, Peijie Yan, Takahito Hasegawa, Mamiko Ozawa, Kaho Maeta, Fumi Nagatsugi, Hirohide Saito, Kaoru R. Komatsu

PMC · DOI: 10.1038/s41467-026-70097-9 · 2026-03-19

## TL;DR

This paper introduces a new method to detect how genetic mutations in RNA affect small molecule binding, focusing on RNA structures called G-quadruplexes.

## Contribution

The novel contribution is the development of BIVID-MaP, a high-throughput method for identifying variant-specific RNA-small molecule interactions.

## Key findings

- BIVID-MaP successfully identifies interactions between RNA G-quadruplexes and small molecules affected by single-nucleotide variants.
- Cancer-associated mutations can significantly alter small molecule binding intensity by modifying RNA G-quadruplex structures.

## Abstract

Individual genetic variations, such as cancer-associated somatic mutations, alter RNA structures, thereby potentially enhancing or inhibiting the binding of RNA-targeting small molecules. However, to date, no approach has been available to identify these variant-specific RNA-small molecule interactions due to technical limitations. Here, we present Binding- and Vinyl-Quinazolinone-Induced Deletion-Based Mutational Profiling (BIVID-MaP), a high-throughput method for detecting RNA-small molecule interactions that combines binding-dependent covalent modification with profiling of deletions upon reverse transcription via deep sequencing. Using BIVID-MaP, we uncovered numerous variant-specific interactions between a G-quadruplex (G4)-binding small molecule and RNAs harboring single-nucleotide variants. Several cancer-associated somatic mutations significantly influence the binding intensity of a small molecule by affecting target G4 structures. These results demonstrate that BIVID-MaP can reveal previously ignored variant-specific RNA-small molecule interactions affected only by a single-nucleotide mutation, which may contribute to the development of RNA-targeting drugs in the future.

Cancer-associated somatic mutations can change RNA structures. Here, the authors develop a method to detect interactions between RNA and small molecules, showing that such mutations can affect small molecule binding by changing the RNA’s G quadruplex structures.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** NME2 (NME/NM23 nucleoside diphosphate kinase 2) [NCBI Gene 4831] {aka NDK2, NDKB, NDPK B, NDPK-B, NDPKB, NM23-H2}, ESCO2 (establishment of sister chromatid cohesion N-acetyltransferase 2) [NCBI Gene 157570] {aka 2410004I17Rik, EFO2, EFO2p, JHS, RBS, hEFO2}, WDR11 (WD repeat domain 11) [NCBI Gene 55717] {aka BRWD2, DR11, HH14, SRI1, WDR15}, MIR4520-1 (microRNA 4520-1) [NCBI Gene 100616401] {aka MIR4520A, hsa-mir-4520-1, mir-4520-1}, MVK (mevalonate kinase) [NCBI Gene 4598] {aka LRBP, MK, MVLK, POROK3}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, MIR1229 (microRNA 1229) [NCBI Gene 100302156] {aka MIRN1229, hsa-mir-1229}, VPS53 (VPS53 subunit of GARP complex) [NCBI Gene 55275] {aka HCCS1, PCH2E, hVps53L, pp13624}, ING2 (inhibitor of growth family member 2) [NCBI Gene 3622] {aka ING1L, ING1Lp, p33ING2}, DAXX (death domain associated protein) [NCBI Gene 1616] {aka BING2, DAP6, EAP1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** Huntington's disease (MESH:D006816), spinal muscular atrophy (MESH:D009134), NMM (MESH:C563209), Cancer (MESH:D009369)
- **Chemicals:** MgCl2 (MESH:D015636), N-Methylmesoporphyrin IX (MESH:C065420), HCl (MESH:D006851), formamide (MESH:C031066), Li+ (MESH:D008094), amine (MESH:D000588), Berberine (MESH:D001599), G4 (MESH:D004003), betaine (MESH:D001622), uracil (MESH:D014498), Tween 20 (MESH:D011136), polyacrylamide (MESH:C016679), Quinazolinone (MESH:D052999), fluorescein (MESH:D019793), glycerol (MESH:D005990), LiCl (MESH:D018021), DTT (MESH:D004229), water (MESH:D014867), K+ (MESH:D011188), MnCl2 (MESH:C025340), EDTA (MESH:D004492), NaCl (MESH:D012965), CMA (MESH:D002715), nucleotide (MESH:D009711), NaOH (MESH:D012972), formic acid (MESH:C030544), hydrogen (MESH:D006859), acetonitrile (MESH:C032159), 9-Amino-6-chloro-2-methoxyacridine (MESH:C010847), methyl vinyl ketone (MESH:C057920), uridine (MESH:D014529), 1,N2-etheno-dG (-), 2-mercaptoethanol (MESH:D008623), phosphate (MESH:D010710), acridine (MESH:D000166), azide (MESH:D001386), salt (MESH:D012492), FAM (MESH:C031179), DMSO (MESH:D004121), vinyl (MESH:D011143), U (MESH:D014501), glutathione (MESH:D005978), thiols (MESH:D013438), KCl (MESH:D011189)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Mutations:** T239W, 3 A > G, C at -6, G7114A, 73 G > A, rs2291418, V for 80-90, G7167A, V for 90-100, 52 C > G, A 20, G1170A, 128 G > A, 18 G > A, G > A
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13002888/full.md

---
Source: https://tomesphere.com/paper/PMC13002888